Automate Your Wheel Strategy on CRDF
With Tiblio's Option Bot, you can configure your own wheel strategy including CRDF - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRDF
- Rev/Share 0.0072
- Book/Share 1.0654
- PB 3.9046
- Debt/Equity 0.0191
- CurrentRatio 6.2231
- ROIC -0.7213
- MktCap 276747740.0
- FreeCF/Share -0.6426
- PFCF -6.4741
- PE -5.6639
- Debt/Assets 0.016
- DivYield 0
- ROE -0.7646
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRDF | Ladenburg Thalmann | -- | Buy | -- | $19 | July 8, 2025 |
| Initiation | CRDF | Jefferies | -- | Hold | -- | $3.5 | June 24, 2025 |
| Initiation | CRDF | Craig Hallum | -- | Buy | -- | $8 | Sept. 6, 2024 |
News
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Cardiff Oncology (CRDF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Cardiff Oncology: Buying The First-Line Onvansertib Strategy
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
Cardiff Oncology's onvansertib shows promise as a first-in-class PLK1 inhibitor for first-line RAS-mutated metastatic colorectal cancer, potentially redefining standard-of-care and achieving blockbuster status. Onvansertib's synergy with bevacizumab and promising clinical data support its pivot to first-line treatment, with potential peak global sales of $1.2B to $2B annually. Despite strong prospects, CRDF faces risks including clinical/regulatory hurdles, market competition, and financial challenges, necessitating potential dilutive funding for Phase III trials and commercialization.
Read More
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Andy Hsieh - William Blair Robert Burns - H.C. Wainwright Albert Lowe - Craig-Hallum Operator Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.
Read More
About Cardiff Oncology, Inc. (CRDF)
- IPO Date 2004-07-27
- Website https://www.cardiffoncology.com
- Industry Biotechnology
- CEO Mark Erlander
- Employees 32